

ResMed Announces Its Premier Portable Oxygen Concentrator, Mobi

Mobi helps oxygen patients embrace active, healthy lifestyles

SAN FRANCISCO, Jan. 8, 2018 /PRNewswire/ -- ResMed (NYSE: RMD, ASX: RMD) today introduced Mobi, its first ResMed-branded portable oxygen concentrator (POC).

Mobi offers an industry-leading balance of oxygen delivery, weight and battery life so that millions with chronic obstructive pulmonary disease (COPD) or other respiratory condition can enjoy ResMed-quality oxygen therapy at home or on the go.

"We have focused decades of patient-centered ResMed technology and design innovation into this POC," said ResMed CEO Mick Farrell. "We've achieved great mobility, comfort and therapy quality in sleep apnea treatment with AirMini, the world's smallest PAP device. Mobi offers that same great balance to the many millions of people who rely on supplemental oxygen to enjoy their highest quality of life."

Mobility is particularly key for oxygen patients with chronic obstructive pulmonary disease. Regular physical activity is shown to lower the risk of hospitalization and death among those with COPD, according to a 2006 study published in *Thorax*: <http://thorax.bmj.com/content/61/9/772>.

"The time is now for portable oxygen," said Farrell. "Our patients demand a device that enables them to get out of their house and travel to visit friends and family. Mobi gives the gift of freedom to millions."

Availability

Mobi will be available to U.S. patients through their home medical equipment (HME) providers later this quarter. ResMed is pursuing clearance to sell in other countries in 2018.

About ResMed

ResMed (NYSE: RMD, ASX: RMD), a world-leading connected health company with more than 4 million cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its 6,000-member team strives to improve patients' quality of life, reduce the impact of chronic disease and save healthcare costs in more than 120 countries. ResMed.com

For media:

Jayne Rubenstein
+1 858-836-6798
news@resmed.com

For investors:

Agnes Lee
+1 858-836-5971
investorrelations@resmed.com

SOURCE ResMed Inc.

[Mobi](#)